Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption

Edward Neuwelt, P. A. Barnett, I. Hellstrom, K. E. Hellstrom, P. Beaumier, C. I. McCormick, R. M. Weigel

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Iodinated monoclonal antibodies (IgG 96.5 and two monomeric Fab fragments 96.5 and 48.7) to melanoma-associated antigens were administered after osmotic blood-brain barrier (BBB) opening in normal rats. Osmotic BBB disruption significantly (P <0.0001) increased monoclonal antibody delivery to the brain. Following BBB opening and intracarotid administration, there was no difference in the disrupted brain concentration integral area under the curve between Fab and IgG over the 72-h experimental period. However, Fab concentration in the disrupted brain was initially higher than IgG, and the clearance was more rapid (P <0.001), decreasing 50% by approximately 4.5 h compared to 25.5 h for IgG. Plasma clearance was also more rapid for the Fab than IgG. The levels decreased 50% by 1.5 h for Fab and 15 h for IgG. The route and timing of antibody infusion had a significant effect on delivery to the disrupted brain with the Fab fragments but not with the intact IgG. Antibody recovered from disrupted brain retained its immunological reactivity as measured by a cell binding assay for at least 24 h. IgG and Fab delivery to the ipsilateral brain after BBB disruption increased (P <0.001) with increasing dose over a more than 3-log dose range. These data provide information applicable to the therapeutic use of monoclonal antibodies in brain tumor treatment.

Original languageEnglish (US)
Pages (from-to)4725-4729
Number of pages5
JournalCancer Research
Volume48
Issue number17
StatePublished - 1988

Fingerprint

Immunoglobulin Fragments
Immunoglobulin Fab Fragments
Blood-Brain Barrier
Immunoglobulins
Melanoma
Immunoglobulin G
Monoclonal Antibodies
Brain
Melanoma-Specific Antigens
Antibodies
Therapeutic Uses
Brain Neoplasms
Area Under Curve

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neuwelt, E., Barnett, P. A., Hellstrom, I., Hellstrom, K. E., Beaumier, P., McCormick, C. I., & Weigel, R. M. (1988). Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Research, 48(17), 4725-4729.

Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. / Neuwelt, Edward; Barnett, P. A.; Hellstrom, I.; Hellstrom, K. E.; Beaumier, P.; McCormick, C. I.; Weigel, R. M.

In: Cancer Research, Vol. 48, No. 17, 1988, p. 4725-4729.

Research output: Contribution to journalArticle

Neuwelt, E, Barnett, PA, Hellstrom, I, Hellstrom, KE, Beaumier, P, McCormick, CI & Weigel, RM 1988, 'Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption', Cancer Research, vol. 48, no. 17, pp. 4725-4729.
Neuwelt, Edward ; Barnett, P. A. ; Hellstrom, I. ; Hellstrom, K. E. ; Beaumier, P. ; McCormick, C. I. ; Weigel, R. M. / Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. In: Cancer Research. 1988 ; Vol. 48, No. 17. pp. 4725-4729.
@article{ca818e92429f48cf9bbffdc987d1da9e,
title = "Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption",
abstract = "Iodinated monoclonal antibodies (IgG 96.5 and two monomeric Fab fragments 96.5 and 48.7) to melanoma-associated antigens were administered after osmotic blood-brain barrier (BBB) opening in normal rats. Osmotic BBB disruption significantly (P <0.0001) increased monoclonal antibody delivery to the brain. Following BBB opening and intracarotid administration, there was no difference in the disrupted brain concentration integral area under the curve between Fab and IgG over the 72-h experimental period. However, Fab concentration in the disrupted brain was initially higher than IgG, and the clearance was more rapid (P <0.001), decreasing 50{\%} by approximately 4.5 h compared to 25.5 h for IgG. Plasma clearance was also more rapid for the Fab than IgG. The levels decreased 50{\%} by 1.5 h for Fab and 15 h for IgG. The route and timing of antibody infusion had a significant effect on delivery to the disrupted brain with the Fab fragments but not with the intact IgG. Antibody recovered from disrupted brain retained its immunological reactivity as measured by a cell binding assay for at least 24 h. IgG and Fab delivery to the ipsilateral brain after BBB disruption increased (P <0.001) with increasing dose over a more than 3-log dose range. These data provide information applicable to the therapeutic use of monoclonal antibodies in brain tumor treatment.",
author = "Edward Neuwelt and Barnett, {P. A.} and I. Hellstrom and Hellstrom, {K. E.} and P. Beaumier and McCormick, {C. I.} and Weigel, {R. M.}",
year = "1988",
language = "English (US)",
volume = "48",
pages = "4725--4729",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption

AU - Neuwelt, Edward

AU - Barnett, P. A.

AU - Hellstrom, I.

AU - Hellstrom, K. E.

AU - Beaumier, P.

AU - McCormick, C. I.

AU - Weigel, R. M.

PY - 1988

Y1 - 1988

N2 - Iodinated monoclonal antibodies (IgG 96.5 and two monomeric Fab fragments 96.5 and 48.7) to melanoma-associated antigens were administered after osmotic blood-brain barrier (BBB) opening in normal rats. Osmotic BBB disruption significantly (P <0.0001) increased monoclonal antibody delivery to the brain. Following BBB opening and intracarotid administration, there was no difference in the disrupted brain concentration integral area under the curve between Fab and IgG over the 72-h experimental period. However, Fab concentration in the disrupted brain was initially higher than IgG, and the clearance was more rapid (P <0.001), decreasing 50% by approximately 4.5 h compared to 25.5 h for IgG. Plasma clearance was also more rapid for the Fab than IgG. The levels decreased 50% by 1.5 h for Fab and 15 h for IgG. The route and timing of antibody infusion had a significant effect on delivery to the disrupted brain with the Fab fragments but not with the intact IgG. Antibody recovered from disrupted brain retained its immunological reactivity as measured by a cell binding assay for at least 24 h. IgG and Fab delivery to the ipsilateral brain after BBB disruption increased (P <0.001) with increasing dose over a more than 3-log dose range. These data provide information applicable to the therapeutic use of monoclonal antibodies in brain tumor treatment.

AB - Iodinated monoclonal antibodies (IgG 96.5 and two monomeric Fab fragments 96.5 and 48.7) to melanoma-associated antigens were administered after osmotic blood-brain barrier (BBB) opening in normal rats. Osmotic BBB disruption significantly (P <0.0001) increased monoclonal antibody delivery to the brain. Following BBB opening and intracarotid administration, there was no difference in the disrupted brain concentration integral area under the curve between Fab and IgG over the 72-h experimental period. However, Fab concentration in the disrupted brain was initially higher than IgG, and the clearance was more rapid (P <0.001), decreasing 50% by approximately 4.5 h compared to 25.5 h for IgG. Plasma clearance was also more rapid for the Fab than IgG. The levels decreased 50% by 1.5 h for Fab and 15 h for IgG. The route and timing of antibody infusion had a significant effect on delivery to the disrupted brain with the Fab fragments but not with the intact IgG. Antibody recovered from disrupted brain retained its immunological reactivity as measured by a cell binding assay for at least 24 h. IgG and Fab delivery to the ipsilateral brain after BBB disruption increased (P <0.001) with increasing dose over a more than 3-log dose range. These data provide information applicable to the therapeutic use of monoclonal antibodies in brain tumor treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023792917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023792917&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 4725

EP - 4729

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -